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I. Introduction
On September 22, 2003, the European Parliament and the Council of the European
Union (EU) formally adopted two regulations' governing the approval, marketing, labeling,
traceability, and importation of food and feed produced using modern biotechnology.2 The
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1. Commission Regulation 1829/2003 of 22 September 2003 on Genetically Modified Food and Feed, 2003
O.J. (L 268) 1, 24 [hereinafter Food and Feed Rule]; Commission Regulation 1830/2003 of22 September2003
Concerning the Traceability and Labelling of Genetically Modified Organisms and the Traceability of Food
and Feed Products Produced from Genetically Modified Organisms and Amending Directive 2001/18/EC,
2003 O.J. (L 268) 1, 24 [hereinafter Traceability and Labelling Rule]. The regulations were published in the
Official Journal of the European Union on October 18, 2003, and entered into force twenty days after publi-
cation. They allow a three month transition for the Traceability and Labelling rule (until January 2004) and a
six month transition period for the Food and Feed rule (until April 2004) to enable affected parties to achieve
compliance with the new rules before they are fully enforced.
2. The popular press typically refers to issues involving bioengineered agricultural commodities and products
as concerning genetically modified (GM) foods or genetically modified organisms (GMOs). However, the term
genetically modified is technically inaccurate, because, as explained by the U.S. Food and Drug Administration
(FDA) in its bioengineering guidance document, most, if not all, cultivated food crops have been genetically
modified. See Draft Guidance for Industry, 66 Fed. Reg. 4706 (Jan. 18, 2001), available at http://vm.cfsan.fda.
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new rules are sweeping in scope and will affect the majority of global food and feed pro-
cessors that sell in EU markets. More significant, however, are the ramifications of these
rules on the trade relationship between the United States and the EU, as well as the inter-
national policy issues raised by the rules.
U.S. food and feed companies doing business in Europe will be particularly burdened by
the new rules due to the widespread use of agricultural biotechnology in the United States.
The United States is the world's leading producer of biotech crops, particularly soybeans
and corn,3 and a large percentage of processed foods made in the United States are derived
from biotechnology. Aside from the effect the new rules will have on the U.S. agriculture
and processed food and feed industry, the rules add another dimension to the ongoing
dispute between the United States and the EU over the use of biotechnology in food and
feed production. This dispute was raised to a new level when, in May 2003, the Bush
administration filed suit with the World Trade Organization (WTO) over the EU's mor-
atorium on the approval of biotech crops and foods. Now many U.S. industry groups are
calling on the Administration to file yet another suit with the WTO challenging the EU's
new Food and Feed and Traceability and Labelling rules. Although it will be some months
before the full impact of these measures is apparent, clearly their implementation will have
a profound effect on the multi-billion dollar food, feed, and commodities industries, and
perhaps beyond.
This article discusses the new regulations, how they alter the existing EU regulatory
framework for genetically modified (GM) food and feed, and some of the problems with
the rules from an international legal perspective. In addition, this article sets forth an anal-
ysis of the commercial, economic, and trade implications of the new rules and offers sug-
gestions on what steps the United States and industry should take in response to the rules.
H. Changes to the Existing Regulatory Framework
Prior to the adoption of the Food and Feed and Traceability and Labelling rules, the EU
employed an extensive patchwork of regulations governing the approval and labeling of
genetically modified organisms (GMOs) and of GM food and feed marketed in the EU.
Below is an overview of this original regulatory regime, as well as a discussion of how the
new rules affect that regulatory framework.
A. EU REGULATORY FRAMEWORK PRIOR TO ENACTMENT OF THE NEW FOOD AND FEED
AND TRACEABILITY AND LABELLING RULES
The EU adopted the regulation known as the Novel Foods Law in 1997 to require pre-
market authorization for GM food products.4 In particular, Regulation 258/97 governs food
safety assessments and labeling for most GM foods. More specifically, the regulation re-
quires that consumers be informed of any property that makes a novel food or ingredient
gov/-dms/biolabgu.html [hereinafter Guidance]. Though we believe the term bioengineered is more appro-
priately used when discussing this issue, for purposes of uniformity with the EU regulations, the terms genet-
ically modified and genetically modified organisms have been used in this paper.
3. According to U.S. Department of Agriculture (USDA) statistics, in 2002, 75 percent of all soy planted in
the United States was derived from biotechnology, while 34 percent of all corn was derived from biotechnology.
4. Commission Regulation 258/97 of 27 January 1997 Concerning Novel Foods and Novel Food Ingredi-
ents, 1997 O.J. (L 43) 1 [hereinafter Regulation 258/97].
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"no longer equivalent" to its conventional counterpart with respect to composition, nutri-
tional value, or intended use.' Products must bear labels informing consumers of (1) "the
presence of an organism genetically modified by techniques of genetic modification..." or
(2) "the presence in the novel food or food ingredient of material which is not present in
an existing equivalent foodstuff and which gives rise to ethical concerns."6
Council Directive 2001/181 governs the approval of "living" GMOs prior to their en-
vironmental release and commercialization. Directive 2001/18 revised Council Directive
90/220,8 which was the original EU regulation governing the environmental release and
commercialization of GMOs. Although Directive 2001/18 went into effect on October 17,
2002, many Member States have yet to transform this directive into national law.
Council Regulation 1139/989 was adopted to govern the labeling of the bioengineered
corn and soybeans already approved for marketing in the EU prior to the adoption of the
Novel Foods Law. This regulation was amended by Regulation No. 49/2000,10 which es-
tablishes a 1 percent threshold for the labeling of bioengineered corn and soybeans to
accommodate adventitious contamination of identity-preserved (non-bioengineered) crops
with the bioengineered varieties." However, Regulation No. 50/2000 removes the thresh-
old to accommodate adventitious contamination. In addition, Regulation No. 50/20001
extends the bioengineered labeling requirements to any food product that contains "the
presence of an additive or flavouring that is or contains an organism genetically modified
by techniques of genetic modification. .."3 This labeling requirement is also triggered if
the additive or flavoring contains protein or DNA resulting from the bioengineering
process. This analysis does not demand an established de minimis threshold or required
sensitivity.
B. How THE NEW RULES AFFECT THE ExISTING REGULATORY FRAMEWORK
The new Food and Feed and Traceability and Labelling rules will replace three of the
four laws currently governing the regulatory review, commercialization, and labeling of
GMOs and foods containing or produced with GMOs in the EU. In particular, the new
rules will replace Regulations 1139/98, 49/2000, and 50/2000. Although some of its
5. Id. art. 8(l)(a).
6. Id. art. 8(l)(c)-(d).
7. Council Directive 2001/18 on the Deliberate Release Into the Environment of Genetically Modified
Organisms and Repealing Council Directive 90/220/EEC, 2001 OJ. (L 106) 1 [hereinafter Council Directive
2001/181.
8. Council Directive 90/220 of 23 April 1990 on the Deliberate Release Into the Environment of Genet-
ically Modified Organisms, 1990 O.J. (L 117) 15 [hereinafter Council Directive 90/220].
9. Council Regulation 1139/98 of 26 May 1998 Concerning the Compulsory Indication of the Labelling
of Certain Foodstuffs Produced from Genetically Modified Organisms of Particulars Other Than Those Pro-
vided for in Directive 79/112/EEC, 1998 Oj. (L 159)4 [hereinafter Regulation 1139/98].
10. Commission Regulation 49/2000 of 10 January 2000 Amending Council Regulation (EC) No. 1139/98
Concerning the Compulsory Indication on the Labelling of Certain Foodstuffs Produced from Genetically
Modified Organisms of Particulars Other Than Those Provided for in Directive 79/112/EEC, 2000 O.J.
(L 6) 13 [hereinafter Regulation 49/2000].
11. Id. art. 1.
12. Commission Regulation 50/2000 of 10 January 2000 on the Labelling of Foodstuffs and Food Ingre-
dients Containing Additives and Flavourings That Have Been Genetically Modified or Have Been Produced
From Genetically Modified Organisms, 2000 Oj. (L 6) 15 [hereinafter Regulation 50/2000].
13. Id. art. 2(d).
SPRING 2004
58 THE INTERNATIONAL LAWYER
provisions will be amended by the Food and Feed rule, the Novel Food Law will remain
in place for novel foods that are not genetically modified. Finally, both rules will amend
Council Directive 2001/18 on the deliberate release of GMOs into the environment.
III. Specifics of the Traceability and Labelling Rule
A. OBJECTIVE
According to the Explanatory Memorandum, the Traceability and Labelling rule was
needed because the existing regulatory framework failed to directly address the trace-
ability and labeling of products produced from GMOs, did not provide a definition of
traceability for GMOs, did not set forth the objectives of traceability, and did not provide
a complete approach for implementation of a traceability system.' 4 The Traceability and
Labelling rule thus seeks to build upon the foundation of requirements set forth in Di-
rective 2001/18 and establish a harmonized framework for the traceability of products
derived from GMOs.
B. SCOPE
The rule applies to the following at all stages of marketing:
* products consisting of or containing GMOs;
* foods and food ingredients, including food additives and flavorings, produced from GMOs;
and
* feed materials, compound feedingstuffs, and feed additives produced from GMOs.
C. GENERAL TRACEABILITY REQUIREMENTS
The rule defines traceability as "the ability to trace GMOs and products produced from
GMOs at all stages of their placing on the market through the production and distribution
chains."' 5 Tracking the movement of GMOs and products derived from GMOs through
the production and distribution chains will be accomplished by traceability requirements.
These requirements will be based on information, gathered through all the stages of mar-
keting, regarding such products. The intent is for the traceability system to facilitate the
withdrawal of products when a risk to human health or the environment is established,
allow for targeted monitoring of the potential effects of products on human health and the
environment, and provide control and verification of labeling claims.
To ensure a harmonized system for tracing products through all stages of marketing,
operators 6 must enact procedures to carry out the following:
* establish and maintain systems and procedures to identify to whom and from whom products
are made available;
* transmit specified information concerning the identity of a product in terms of the individual
GMOs it contains or whether it is derived from GMOs;
14. Traceability and Labelling Rule, supra note 1, at 2 (Explanatory Memorandum).
15. Id. art. 3(3).
16. The Traceability and Labelling Rule defines operator as a "person who places a product on the market
or who receives a product that has been placed on the market in the Community.. at any stage of the production
and distribution chain, but does not include the final consumer." Id. art. 3(5).
VOL. 38, NO. 1
FROM FARM TO FORK 59
- retain all specified information for a period of five years and make it available to the com-
petent authorities on demand."
Because many producers already have traceability systems in place, the rule does not
specify the means by which this information must be transmitted and retained. Thus, to
the extent existing systems are in place to transmit and retain the required information,
those existing systems theoretically are sufficient and may be used.
The rule makes a distinction between GMOs and products produced from GMOs, noting
that the objectives for the traceability of each group are not identical and that the specified
information required to be transmitted and retain for each group differs." In this regard,
the rule provides for the traceability of individual GMOs within a product, on the basis of
its authorized transformation event; while the traceability of products produced from
GMOs do not require identification of the GMOs from which they are produced.
D. TRAcEABILITY AND LABELLING FOR GMOs
1. Specific Requirements for Traceability
Existing Commission law requires the implementation of measures to ensure the trace-
ability of GMOs at all stages of marketing. 19 However, this requirement does not differ-
entiate between uses of GMOs. In addition, Council Directive 2001/18 requires the im-
plementation of monitoring plans to trace and identify any direct, indirect, immediate,
delayed, or unforeseen effects on human health or the environment. 20 Because possible
effects from GMOs are dependent upon the inherent nature of the GMO or the specific
transformation event, the Traceability and Labelling rule calls for the specific identification
of each GMO and its associated traits and characteristics in order to facilitate targeted
withdrawals and environmental monitoring. As a result, according to the rule, a unique
means of identifying each GMO is necessary. To facilitate this identification, operators must
transmit the following specified information to the operator receiving the products: (1) that
the product contains/consists of GMOs, and (2) the unique codes relating to the GMOs.2'
2. Unique Codes
The Traceability and Labelling rule takes the authorized transformation event22 from
which the GMO is developed as its point of departure. The rule requires that the Com-
mission establish a system to develop and assign unique codes2" to the GMOs.2 4 In fur-
therance of this requirement, the rule recommends the establishment of a committee to
develop a system for the development and assignment of the unique GMO codes.2
17. Id. art. 4(A).
18. Id. art. 4(A), art. 5.
19. See generally Council Directive 2001/18, supra note 7.
20. Id. art. 6. See also generally Annex III.
21. Traceability and Labelling Rule, supra note 1, art. 4(A)(1).
22. The Explanatory Memorandum provides that a transformation event is where a conventional organism
is transformed through the introduction of modified DNA sequences, resulting in formation of a GMO. The
introduction of these sequences ultimately determines the modified characteristics of the GMO (for example,
insect resistance or herbicide tolerance). Id. at 4 (Explanatory Memorandum).
23. The rule defines unique identifier as a "simple numeric or alphanumeric code which serves to identify
a GMO on the basis of the authorised transformation event from which it was developed and providing the
means to retrieve specific information pertinent to that GMO." Id. art. 3(4).
24. Id. art. 8.
25. Id. art. 10.
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The unique codes must be transmitted and retained from the time the GMOs are first
placed on the market through to their final and ultimate use as a food or feed or for
processing.16 The purpose of this requirement is to enable the traceback of GMOs through
the production and distribution chains. In addition, the unique code information will fa-
cilitate labeling, and, in the case of an unforeseen event, post-market withdrawals.
3. Sampling and Testing
The rule's Explanatory Memorandum acknowledges that, particularly in the case of im-
ports from third countries (for example, bulk shipments of commodity crops), analytical
testing and sampling may be needed if the exporter fails or is unable to supply the importer
with information regarding the identity of the products, in particular the GMOs they con-
tain.27 The rule does not require mandatory testing at each stage of marketing. However,
the rule does direct the Commission to develop technical guidance on sampling and testing
methodologies prior to enactment of the regulation in order to facilitate a coordinated
approach for inspection and control by Member States. 8
4. Labelling
Currently, pursuant to Directive 2001/18, the labeling of GMOs is required at all stages
of marketing.29 The Traceability and Labelling rule places a legal obligation on operators
to label prepackaged products in accordance with 2001/18.30 Specifically, the rule requires
that operators ensure that products are labeled "this product contains genetically modified
organisms."3 'Where labeling is not possible, as with bulk commodities that are not pack-
aged, operators must ensure the appropriate information is transmitted with the product
to allow for labeling at a later time.,2
E. TRACEABILITY FOR PRODUCTS PRODUCED FROM GMOs
The new rule builds on existing traceability systems required by other European Com-
munity (EC) laws,33 with the objective of extending those requirements to include infor-
mation regarding whether a product is produced from GMOs. In particular, the following
information must be transmitted to operators receiving products produced from GMOs:
* an indication of each of the food ingredients, including additives and flavorings, derived from
GMOs;
* an indication of each of the feed materials or additives produced from GMOs;
* where products do not have an ingredient list, an indication that the product is produced
from GMOs.
3 4
26. Id. art. 4(A)(1)(b).
27. Id. at 6 (Explanatory Memorandum).
28. Id. art. 9(2).
29. See Council Directive 2001/18, supra note 7.
30. See Traceability and Labelling Rule, supra note 1, art. 4(B).
31. Id. art. 4(A).
32. Id.
33. See, e.g., Council Regulation 1760/2000 of 17 July 2000 Establishing a System for the Identification and
Registration of Bovine Animals and Regarding the Labelling of Beef and Beef Products and Repealing Council
Regulation (EC) No 820/97, 2000 OJ.'(L 204) 1. See also Council Directive 89/396 On Indications or Marks
Identifying the Lot to Which a Foodstuff Belongs, 1989 OJ. (L 186) 21.
34. Traceability and Labelling Rule, supra note 1, art. 5(1).
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Finally, the rule envisions that the traceability requirements will provide the basis for
extending current labeling requirements for foods produced from GMOs to cover all foods
and food ingredients produced from GMOs.35
IV. Specifics of the Food and Feed Rule
A. OBJECTIVES
The Food and Feed rule has three objectives:
* to ensure the protection of human life and health, animal health and welfare, the environ-
ment, and consumers' interest in relation to GM food and feed, while ensuring the effective
functioning of the internal market;
* to establish Community procedures for the assessment, authorization, and supervision of
genetically modified food and feed; and
* to establish provisions for the labbeling of GM food and feed.
3 6
B. SCOPE
The rule covers food and feed containing, consisting of, or produced from GMOs. In
addition, the rule extends the scope of existing Community legislation on GMOs to also
cover feed produced from GMOs, as well as a specific evaluation of the genetic modification
relating to substances such as food additives, flavorings, or feed additives, when produced
from GMOs.
Significantly, the rule applies to products producedfrom a GMO, but does not apply to
products produced with a GMO. 37 The rule defines "produced from GMOs" as "derived,
in whole or in part, from GMOs, but not containing or consisting of GMOs."3 8 Produced
with GMOs refers to a product that is produced with the assistance of a GMO, but has no
material derived from the GMO present in the end product29 As a result, cheese produced
with GM enzymes that are not present in the end product would not be subject to the
regulation. The final product obtained from animals fed with GM feed or treated with GM
medicinal products would also not be subject to the regulations.
The rule is based on the one door-one key principle, whereby it will be possible to file
a single application to obtain authorization for both the (1) deliberate release of a GMO
into the environment, pursuant to the criteria set forth in Directive 2001/18 and (2) the
use of that GMO in food and/or feed, pursuant to the criteria set forth in this rule.4
Authorization will be granted subject to a single risk assessment process, addressing both
the environmental risk and risk to human and animal health, to be conducted by the Eu-
ropean Food Authority (EFA), as well as a single risk management process involving the
Commission and Member States through a regulatory committee procedure. 41
35. Id. at 8 (Explanatory Memorandum).
36. Food and Feed Rule, supra note 1, art. 1.
37. Id. art. 3(1)(c).
38. Id. art. 2(10).
39. See id. at 4 (Explanatory Memorandum).
40. Id. art. 5.
41. Id. art. 6.
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C. PRINCIPLES OF THE AUTHORIZATION PROCEDURE
The rule sets out the procedures for submitting an application for the approval of GM
food and feed.42 Applications must be made to the national competent authority who will
then inform the EFA.43 The rule allows for public involvement in the authorization process
whereby a summary of the application and opinion of the EFA will be made available to
the public, which may then comment on the opinion for thirty days."
Products approved under the proposed regulation will be listed in a registry of GM food
and feed (the Community Register of Genetically Modified Food and Feed), which includes
product specific information, studies demonstrating the safety of the product, and detection
methods that must be provided by the applicant to facilitate control. 4" The initial author-
ization will be granted for a period of ten years.-
Authorizations granted under existing Community law would remain in place under the
rule, provided that additional information concerning the risk assessment and the methods
for sampling and detection (including samples of the food and feed) are submitted to the
EFA within six months of the enactment date of this regulation. 41 The consequence of
failing to comply with this requirement is that food or feed currently approved for mar-
keting in the EU will no longer be viewed as approved.
D. LABELLING
As discussed previously, labeling requirements for GM food are currently set forth in
several pieces of Community legislation. In addition, labeling is currently required for GM
feed pursuant to Directive 2001/18. However, Directive 2001/18 applies only to live GMOs,
not to feed produced from GMOs but no longer containing GMOs.
4 s
Labelling is currently triggered by the presence of DNA or protein resulting from genetic
modification. However, the new rule extends the current labeling provisions to all GM food
and feed regardless of the detectability of DNA or protein.49 As a result, food that consists of,
contains, or is produced from GMOs would have to be labeled as such even in the absence
of detectable DNA or protein. This provision is a significant change from the current
regulatory regime and will result in the required labeling of numerous products that do not
currently require labeling, for example, highly refined oils of GM origin. The Traceability
and Labelling rule is intended to facilitate the labeling required under the Food and Feed
Rule.
42. See id. art. 5.
43. Id. art. 5(2).
44. Id. art. 6(7).
45. Id. art. 7(5), art. 28.
46. Id. art. 7(5).
47. Id. art. 8(1).
48. The issue of labeling requirements for GM feed is further complicated by the fact that until the second
revision of Directive 90/220/EEC, which was the predecessor to 2001/18/EC, there was no requirement for
the labeling of GM feed. As a result, currently four authorizations for GM feed require labeling, while four
other authorizations do not.
49. Food and Feed Rule, supra note 1, arts. 12-13.
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E. ADVENTITIOUS CONTAMINATION
To provide for situations where minute traces of GM material may be present in food
and feed as a result of adventitious or technically unavoidable contamination, the rule es-
tablishes a threshold of 0.9 percent for approved GMOs5 ° For unapproved GMOs, the
threshold is 0.5 percent for three years after the enactment date of the regulations, after
which time it will drop to 0 percent.51
V. The EU's New Rules and the WTO's Agreement on
Technical Barriers to Trade
At least some provisions of the new EU rules, the labeling and traceability requirements
in particular, are likely violative of international law principles embodied in the VWTO's
Agreement on Technical Barriers to Trade (TBT Agreement),5 2 and possibly the Agreement
on Sanitary and Phytosanitary Measures (SPS Agreement),53 to which all WTO Member
nations subscribe as a condition of membership. The EU has argued that the new rules are
necessary, not only to protect the health and safety of its citizens but also to facilitate
consumer choice. However, the regulatory regime in place prior to enactment of these new
rules most certainly achieved these objectives, although they too were arguably violative of
WTO agreements.
Article 2.2 of the TBT Agreement provides that technical regulations shall not be "pre-
pared, adopted or applied with a view to or with the effect of creating unnecessary obstacles
to international trade. ' '5 4 To ensure that no unnecessary obstacles are erected, the Agree-
ment requires that any regulations enacted "shall not be more trade-restrictive than nec-
essary to fulfill a legitimate objective.""5
The labeling and traceability requirements set forth in the EU's new rules are an obstacle
to trade because they will siguificantly burden any processor of GM food or feed, as well
as any other operator within the supply chain of those products. In addition, EU consumers
will not purchase GM food products, and retail stores are increasingly refusing to stock the
products on their shelves. Thus, imposing a costly system of traceability on food processors
and requiring them to label their products as being derived from a GM source greatly
increases the likelihood that those products will go unsold in markets employing mandatory
bioengineered labeling.
Second, the labeling requirements are unnecessary, because, as discussed below, other,
less restrictive measures are already in place to address safety concerns, and the require-
ments institute, rather than eradicate, deceptive practices by misleading consumers to
50. Id. art. 12(2).
51. Id.
52. Agreement on Technical Barriers to Trade, Apr. 12, 1979, 18 I.L.M. 1079 (1979), available at http://
www.wto.org [hereinafter TBT Agreement].
53. The WTO Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement),
available at http://www.wto.org (last visited Jan. 16, 2004). The SPS Agreement requires that WTO member
nations "ensure that their sanitary or phytosanitary measure is applied only to the extent necessary to protect
human, animal or plant life or health, [and] is based on scientific principles and is not maintained without
sufficient scientific evidence ...."
54. TBT Agreement, supra note 52, art. 2.2.
55. Id.
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believe that bioengineered food is of a lesser quality than conventional food and that it
presents safety risks. Further, the labeling requirements are unnecessary because they are
inconsistent with prior approvals of the bioengineered commodity. In essence, by approving
a bioengineered agricultural commodity under existing regulations, and then further re-
quiring that the product be labeled as being bioengineered, the initial regulatory approval
for the commodity is being withdrawn. On one hand, the commodity or food product is
given approval based on science and the law, while on the other hand, a labeling requirement
based on fear and political concerns is implemented, which results in a de facto sanction
against the products. It is certainly unnecessary to require label differentiation of products
otherwise equal in safety and quality.
Finally, the labeling and traceability requirements do notfufill a legitimate objective and
are more trade restrictive than necessary even if such a legitimate objective exists. For
example, voluntary labeling of food products that do not contain ingredients derived from
bioengineered sources would address concerns about informing consumers about the nature
of their food products without effectively closing entire markets to U.S. bioengineered food
products.
A. LABELLING AND TRACEABILITY Do NOT FULFILL A LEGITIMATE OBJECTIVE
Although the TBT Agreement does not expressly define what constitutes a legitimate
objective, it does set out examples, such as "protection of human health or safety, animal
or plant life or health, or the environment" and "the prevention of deceptive practices.
56
Neither of these objectives provides a legitimate basis for the enactment of mandatory
bioengineered labeling, particularly with regard to the EU labeling and traceability
requirements.
1. Protection of Health, Safety, and the Environment
First, any safety concerns the EU could point to as justification for the bioengineered
labeling requirements have been addressed through Council Directives 90/220 and 2001/
18, which require an assessment to be carried out by the EU's Scientific Committee on
Plants before a bioengineered organism can be placed on the market. The aim of the
assessment is to evaluate any risks to human health and to the environment connected with
the release of the bioengineered organisms. Any bioengineered organism being reviewed
pursuant to these directives must undergo rigorous testing before it is granted approval. In
fact, to date the EU has approved only eight bioengineered agricultural commodities, and
in 1999, instituted a moratorium on the approval of any new bioengineered organisms.57
Furthermore, the EU's Novel Foods Regulation"' requires the approval of all novel foods
and food ingredients, including those made from bioengineered agricultural commodities.
The requirements of Directives 90/220, 2001/18, and the Novel Foods Regulation,
therefore, provide substantial and sufficient safeguards to ensure that any bioengineered
food products marketed in the EU will be safe for the environment and for consumers.
Furthermore, as provided by Article 2.2 of the TBT Agreement, when assessing risks pre-
56. Id.
57. This moratorium is the subject of the WTO suit filed by the United States and several other nations in
May 2003.
58. Commission Regulation 258/97, supra note 4.
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sented by a legitimate objective (for example, safety concerns) Members implementing
technical regulations are to consider, inter alia, "available scientific and technical informa-
tion, related processing technology or intended end-uses of products."59 However, under
the EU regulations governing the pre-market approval of bioengineered agricultural com-
modities and foods, these factors have already been considered.
If bioengineered foods and ingredients are safe enough to be approved for human con-
sumption within the EU, as has been the case, the addition of stigmatizing warnings is
unnecessary. This is particularly true when the labeling and traceability requirements are
expensive or extremely burdensome for the food industry to follow and when they will only
lead to unwarranted consumer fear and rejection of the bioengineered foods.
1. Prevention of Deceptive Practices
The EU labeling requirements are also not justified on the ground of prevention of
deceptive practices. On the contrary, mandatory bioengineered labeling, if anything, pro-
motes consumer deception. A failure to label the source of a given food ingredient is not
deceptive. Indeed, other than bioengineered labeling requirements, no other requirements,
of which we are aware, require the source of a food ingredient or the method of its pro-
cessing to be declared. In the current climate, an unqualified requirement to declare a
bioengineered source is itself deceptive, because it implies that the food is less safe or of
lesser quality than a conventional food. This implication is shown to be false by virtue of
the EU's own scientific pre-market review and approval.
Moreover, the FDA, in a Guidance to the industry on voluntary labeling for biotech
foods, discussed how consumers are easily misled by information about the bioengineered
status of food products.6 The Guidance states the FDA's view that bioengineered labeling
"may be misleading if it fails to disclose facts that are material in light of representations
made about a product or facts that are material with respect to the consequences that may
result from use of the product."'6' The Guidance then cites particular examples of bioen-
gineered labeling that might prove misleading or technically inaccurate to the consumer.
For example, FDA expressed particular concern that the term "genetically modified" is
misleading because terms:
that include the word "modified" are not technically accurate unless they are clearly in a context
that refers to bioengineering technology. "Genetic modification" means the alteration of the
genotype of a plant using any technique, new or traditional. "Modification" has a broad context
that means the alteration in the composition of food that results from adding, deleting, or
changing hereditary traits, irrespective of the method .... Most, if not all, cultivated food crops
have been genetically modified." (emphasis added). 62
In lieu of the term "genetically modified," FDA suggests the use of the terms "bioengi-
neered" or "genetically engineered." The EU labeling requirements, however, expressly
employ the term "genetically modified" which FDA found problematic. The new Trace-
ability and Labelling and Food and Feed Rules also require the use of these terms.
63
59. TBT Agreement, supra note 52, art. 2.2.
60. See Guidance, supra note 2.
61. Id. at 4.
62. Id. at 5-6.
63. Traceability and Labelling Rule, supra note 1, art. 4(B)(6); Food and Feed Rule, supra note 1, art. 12.
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B. EVEN IF A LEGITIMATE OBJECTIVE EXISTS, THEY COULD BE ADDRESSED THROUGH LESS
TRADE-RESTRICTIVE MEASURES
Assuming a legitimate objective of responding to a perceived consumer demand for
information exists, the EU could fulfill this objective in a less trade-restrictive manner
by providing a framework for voluntary labeling" of food products that did not use
bioengineered-derived ingredients, as long as statements concerning the absence of such
ingredients are not misleading. Under this framework, consumers who prefer to avoid
bioengineered ingredients, and who will not object to paying the extra cost of foods not
containing them, will have the opportunity to drive such a market. Such an arrangement
would be fairer to consumers and makes more economic sense. Consumers would receive
an actual choice between bioengineered and non-bioengineered products, as opposed to
the dominance of non-bioengineered products encouraged by the current regime. More-
over, the additional costs of non-bioengineered products would be borne by those who
desire such products, rather than forced upon the entire population.
VI. Analysis of the Commercial, Economic, and Trade
Implications of the Rules
The EU's new biotech rules have the potential to exacerbate the already growing dis-
ruptions in trade in commodities and finished food products between the United States and
the EU Member States. In addition, a template is now in place for developing countries to
take essentially the same action, or some variant. Previously the subject of a protracted
dispute between the EU and the United States for several years since the revision of Council
Directive 90/220, the rules send an unmistakable signal that the EU is abandoning all traces
of substantial equivalence and content-based labeling in favor of process-based labeling,
based at least in part on the Precautionary Principle. The rules also rely on so-called other
non-scientific factors and the provisions of the Convention on Biological Diversity's Bio-
safety Protocol. These provisions were never intended to apply to food products but are in
fact the basis for the entire EU revision process, including the initial changes to Directive
90/220 that set these directives into motion several years ago.
Although some of the parties in the Commission, with whom U.S. government and
industry have negotiated, realized that these rules (if enacted) would do severe damage to
the food economy, they were unable to persuade their colleagues of the potential for harm.
The assumption that the infeasibility of the rules would ultimately cause their undoing was
overly optimistic: those parties who promoted the changes demonstrated little concern for
64. If voluntary labeling were to take place, the EU and other international authorities would need to take
care to prevent misleading claims, i.e., an unqualified claim of "contains no ingredients derived from bioen-
gineered sources" is misleading because it implies that the food is safer and of better quality than foods con-
taining bioengineeredo-sourced ingredients. For example, as noted by the FDA in its voluntary labeling
guidance:
A statement that a food was not bioengineered or does not contain bioengineered ingredients may be
misleading if it implies that the labeled food is superior to foods that are not so labeled. FDA has
concluded that the use or absence of use of bioengineering in the production of a food or ingredient
does not, in and of itself, mean that there is a material difference in the food. Therefore, a label
statement that expresses or implies that a food is superior (e.g., safer or of higher quality) because it is
not bioengineered would be misleading.
Guidance, supra note 2, at 6.
VOL. 38, NO. 1
FROM FARM TO FORK 67
whether U.S. industry could comply, and some are probably hoping that it cannot comply.
Much of the problem is discernible from the underlying assumptions inherent in the frame-
work. The continued insistence on the use of pejorative descriptors, such as GMO and
adventitious contamination, is a signal example. The very use of those words is suggestive
more of a regulatory framework for toxic waste than it is for the purpose supposedly
intended.
Complicating the problem is that many of the parties in favor of labeling are less con-
cerned with consumer choice and more intent upon securing a trade advantage. This desire
is nowhere more evident than in the blatantly discriminatory exemption of enzymes and
processing aids from the scope of the labeling provisions. If the concern for the consumer's
right to know that the process of recombination was used truly is paramount, regardless of
the detectability of protein or DNA, then the rule would have included enzymes used as
processing aids in such key exports as wine, beer, and cheese. As it stands, the exclusion is
blatantly discriminatory.
The readily predictable effects of implementation of these rules will be several:
- U.S. manufacturers will experience increased costs related to securing, collating, transmitting
and maintaining records for each and every product and ingredient that contains or may be
derived from biotechnology, regardless of whether protein or DNA is detectable. The ad-
ventitious contamination threshold loophole, for labeling purposes, is now closed. Unless a
manufacturer knows for certain that its product or ingredient has only been subjected to
adventitious contamination (and is prepared to document that fact), rather than having been
produced in part or in whole as a result of genetic recombination, labeling is a requirement.
Ultimately, the result will be increases in production costs and, inevitably, consumer prices.
Any manufacturer that is dependent on transgenically-sourced materials loses a competitive
advantage in proportion to that dependence as long as consumer choice is denied.
The legal penalties for failure to comply are not yet clear, but the commercial penalties will
be far more severe. Given the degree of attention this initiative has received, and the lack of
acceptance accorded to the old regulatory system, EU member state officials will have little
choice but to enforce compliance if they are to maintain their credibility with the public.
Activist groups will be watching closely, and taking their own action, in concert with some
sectors of the media, to ensure compliance. The consequences of failure to comply are just
as, if not more serious, in their effect on relations with distributors and consumers as are the
expected fines. The margin for error in the production process will approach zero, and each
and every U.S. brand (and eventually some European brands as well) will be placed under a
microscope.
Implementation of these rules will give additional momentum to activist groups and like-
minded regulators in a number of developing markets. Many countries are in the process of
developing labeling regulations, and the EU rules already have been copied by other coun-
tries anxious to avoid seeming to be lax in managing this issue. The results would create
large biotech free zones throughout the world in which U.S. farmers, grain handlers, and
ingredient suppliers are powerless to provide adequate and legally merchantable product.
The resulting demand for GM-free soy, corn, and canola, among other products, will also
result in increased raw material prices, with such increases proportionate to the number and
size of the countries adopting similar provisions.
The long-term implications are potentially more serious and far more difficult to predict.
As onerous as the provisions are, the principles on which the rules are based are even more
dangerous. In one series of actions, the EU regulatory, legislative, and political apparatus
has:
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* rejected the doctrine of substantial equivalence;
* reinterpreted the Biosafety Protocol;
* given additional support to the notion of a Precautionary Principle;
* invoked factors other than science and food safety in making a decision that will affect untold
billions of dollars in food exports; and
* undermined thoroughly its credibility by first insisting that the process was sufficient to
trigger labeling and then, in the same document, exempting enzymes used as processing aids
that might be derived from recombinant sources. Despite promises by EU officials that the
exemption for enzymes as processing aids would be removed during the co-decision process,
the exemption has remained in the document from its inception.
Moreover, the rules almost certainly violate the TBT Agreement and perhaps the SPS
Agreement. They also decidedly undermine the foundations of the WTO. Worse, the rules
throw into doubt the credibility, viability, and relevance of such science-based institutions
as the Codex Alimentarius Commission, which is in the midst of addressing these issues.
Finally, the precedent is unacceptable. Regardless of the importance to a given manufac-
turer of biotech labeling regulations, the bases upon which these rules are made are far
more critical as a matter of principle. If these justifications are allowed to stand in support
of the proposed regulations, they are transferable to virtually any product, ingredient, or
technology that may be objectionable to one interest group or another. This action directly
affects technological innovation and competitiveness and extends far beyond the realm of
food. These principles will be used against American and European industry alike. Both
the Precautionary Principle and the doctrine of Other Legitimate Factors are ripe for use
across a spectrum of industries, and the consequences are limited only by the imaginations
of politically-motivated (or intimidated) risk managers. For these reasons, a challenge
should be contemplated at the earliest feasible opportunity, regardless of any speculative
notions regarding the possibilities of success. The underlying principles at stake transcend
the issue presently under consideration. Nanotechnology and future innovations in a host
of other areas and technologies that are today unknown will be governed by the template
that emerges from this process. As a consequence, the United States and other affected
countries should seek to ensure that the example is a legally, morally, and commercially
sustainable one. The regulatory scheme contemplated at present does not fit these essential
criteria.
VII. What Should be Done
Industry cooperation from farm to table has always been desirable. The cooperation is
now mandatory. In addition, the food chain should be extended to include commodity
traders, shippers, freight handlers, insurers, and reinsurers. Many in the Commission and
in Parliament have little understanding of the enormous complexity of the U.S. grain han-
dling system. Grain can be warehoused for years at its origin, consolidated with shipments
from numerous other locations, shipped to one destination, and converted (or flipped) to
yet another destination on the high seas. The grain is often then warehoused by the im-
porter and re-exported.
As a consequence of the new rules, parallel markets for biotech and non-biotech grain
are likely to emerge because the costs will be different. For this reason, commodity traders
should be brought into immediate discussions with the food and commodities industries so
that they might be briefed and their opinions sought. Their response could serve to generate
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a more robust debate, encompassing issues of dollars and cents that have thus far been
abstractions.
The United States has solid arguments against these rules:
- A convincing argument exists relative to the TBT Agreement, since under Codex, consumers
only have the right to know what could harm them, and because voluntary labeling is available
for qualities that pertain to consumer preference (such as halal, kosher, and organic). The
Commission's rules make the specious claim that failure to label biotech foods would some-
how mislead the consumer and that the costs are negligible. Both of these assertions are
easily refuted.
* The United States has persuasive arguments in the SPS arena as well, since biotech food is
safe and no proof to the contrary has ever been found. The Precautionary Principle, despite
protests to the contrary from many in the Commission, appears nowhere in the SPS Agree-
ment. Traceability itself is based on an amorphous, unquantifiable, and unspecified prospec-
tive risk to human or environmental health that requires drastic pre-emptive action. Such a
philosophical construct was damaging enough when applied to an issue such as bovine spon-
giform encephalopathy (BSE); it would be even more problematic if and when it is applied
to biotech commodities and food products.
The United States also has a compelling argument regarding the relationship between
environmental treaties and the WTO. The Preamble of the Biosafety Protocol itself war-
rants legal challenge, and the V/TO is likely to be loath to surrender its prerogatives to the
Convention on Biological Diversity.
The ramifications of these rules for the U.S. food and commodity industries are pro-
found, particularly given the potential for the development of similar initiatives in large
developing-country markets. Worse, the precedent will have been established that will make
each successive instance of non-science based regulation, based instead on ethereal socio-
political principles, more easily digestible than the last.
That the Commission has become more and more bold in promoting this regime is surely
not a coincidence, as Poland and Hungary, with their considerable grain supplies, have
moved ever closer to membership in the EU. Finally, and perhaps most important, the
point should be made that the rules are neither consistent nor credible. The basis of the
rules is the consumer's fundamental right to know that the process of genetic recombination
was used, but the labeling of enzymes used as processing aids was specifically and pointedly
exempted. When this inconsistency was pointed out to the Commission two years ago,
promises were made that this was unintentional and that the exemption would be removed
during the negotiation process. Nearly three years have passed and the exemption remains
firmly embedded in the final version of the rules. This exemption is wholly inconsistent
with the spirit on which the rules were supposed to have been based and does as much to
undermine their credibility as any other single factor. If for no other reason, the rules should
be challenged, just as was the beef hormone decision, to set a clear example and prevent
the adoption of this framework by other trading partners.
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